HDAC Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer

摘要

The present invention relates to a pharmaceutical combination for the treatment of blood cancer, comprising a histone deacetylase (HDAC) inhibitor of formula (I), a proteosome inhibitor or an immunomodulatory drug and a steroidal anti-cancer drug. The pharmaceutical combination of the present invention is a problem of conventional HDAC inhibitors because of the mechanism of inhibition of the compound of formula (1) and its pharmaceutically acceptable salt, proteosome inhibitor or immunomodulatory drug and steroid-based anticancer drug against multiple cancers While pharmacological effects are reduced to the same level, toxicity is reduced and it can be useful for the treatment of blood cancer such as multiple myeloma.